

# TABLE OF CONTENTS

|   |           |
|---|-----------|
| <b>0. Executive Summary .....</b>   | <b>9</b>  |
| <b>1. Basics of Transdermal Drug Delivery .....</b>                         | <b>11</b> |
| <b>Introduction .....</b>   | <b>11</b> |
| Historical landmarks in transdermal drug delivery .....                     | 11        |
| <b>Anatomy and physiology of skin .....</b>                                 | <b>12</b> |
| Transcutaneous absorption .....   | 12        |
| <b>Transdermal versus other methods of drug delivery .....</b>              | <b>12</b> |
| Advantages of transdermal drug delivery .....                               | 13        |
| <i>First-Pass Effect</i> .....  | 13        |
| Drawbacks of transdermal delivery.....                                      | 13        |
| <b>Factors that influence transdermal drug delivery .....</b>               | <b>13</b> |
| <b>Events governing transcutaneous absorption .....</b>                     | <b>14</b> |
| Properties of the skin .....  | 14        |
| Properties of drugs.....  | 15        |
| <i>The role of pH and pharmacokinetics</i> .....                            | 15        |
| <i>Intradermal disposition of drugs after topical application</i> .....     | 16        |
| <b>2. Transdermal Drug Delivery Technologies .....</b>                      | <b>17</b> |
| <b>Introduction .....</b>   | <b>17</b> |
| <b>Local application formulations .....</b>                                 | <b>18</b> |
| Crystalline topical formulations .....                                      | 18        |
| Microemulsions for transdermal drug delivery .....                          | 18        |
| Nanoemulsions for transdermal drug delivery .....                           | 19        |
| Transdermal gel technology .....  | 19        |
| Film forming polymeric solutions.....                                       | 20        |
| Biphax system.....  | 21        |
| <b>Penetration enhancers.....</b>   | <b>21</b> |
| Chemical enhancers .....  | 21        |
| <i>Nitric oxide-based transdermal drug delivery</i> .....                   | 23        |
| Vesicular transdermal carriers .....  | 23        |
| <i>Liposomes</i> .....  | 24        |
| <i>Transfersomes</i> .....  | 24        |
| <i>Ethosomes</i> .....  | 25        |
| <i>Elastic vesicles for transdermal drug delivery</i> .....                 | 25        |
| <i>Nanovesicles for transdermal drug delivery</i> .....                     | 26        |
| <b>Transdermal patches .....</b>  | <b>26</b> |
| Adhesives for transdermal patches .....                                     | 27        |
| Commercial development of transdermal patches .....                         | 28        |
| Innovations in transdermal patches.....                                     | 29        |
| <i>e-Patch™ controlled release micropump system</i> .....                   | 29        |
| <i>Patchless Transdermal Delivery System</i> .....                          | 30        |
| <i>Metered-dose transdermal system</i> .....                                | 30        |
| <b>Use of physical modalities to facilitate transdermal transport .....</b> | <b>31</b> |
| Transdermal electrotransport .....  | 31        |
| Electroporation .....   | 31        |
| <i>Drug delivery by electroporation</i> .....                               | 32        |
| Cryoelectrophoresis.....  | 33        |
| Iontophoresis .....   | 34        |
| <i>Iontophoresis compared with electrophoresis</i> .....                    | 35        |
| <i>Application of iontophoresis for drug delivery</i> .....                 | 35        |
| <i>Companies with technologies for drug delivery by iontophoresis</i> ..... | 36        |
| Combination of electrophoresis and iontophoresis .....                      | 37        |
| <i>Dermaportation</i> .....   | 37        |
| Radiofrequency-driven transdermal delivery .....                            | 37        |
| Microporation .....   | 38        |
| Transcutaneous drug delivery by electropulsation .....                      | 38        |
| Companies involved in electroporation-based drug delivery .....             | 39        |
| Electrode Scanning System .....   | 39        |
| Use of electrostatic force in skin patch technology.....                    | 39        |
| Multiple Absorption Kinetic System.....                                     | 40        |
| Transdermal drug delivery facilitated by heat .....                         | 40        |
| <i>Controlled, heat-aided drug delivery</i> .....                           | 40        |
| Ultrasound .....  | 41        |
| Magnetophoresis.....  | 43        |
| Use of lasers for transdermal drug delivery .....                           | 43        |
| <i>Transdermal drug delivery by laser-induced pressure waves</i> .....      | 43        |

|   |           |
|---|-----------|
| <i>Transdermal drug delivery by laser-assisted changes in skin</i> .....          | 43        |
| Transdermal delivery by gas under pressure .....                                  | 44        |
| <i>Transdermal delivery with PowderJect gas gun</i> .....                         | 44        |
| <i>Microscission induced by gas</i> .....   | 44        |
| <b>Role of microelectronics in transdermal drug delivery</b> .....                | <b>45</b> |
| <b>Microneedles and dermal microinjection technologies</b> .....                  | <b>45</b> |
| Microneedle patch .....   | 46        |
| AdminPatch® microneedle array .....   | 47        |
| Biodegradable microneedles .....  | 47        |
| Ceramic microneedle arrays .....  | 48        |
| Dissolvable microneedle patches .....   | 48        |
| Microneedle arrays for drug delivery .....  | 48        |
| MicroPyramid™ microneedles .....  | 49        |
| Microstructured Transdermal Systems .....   | 49        |
| Microneedle Array Patch technology .....  | 50        |
| Microneedle transdermal chip .....  | 50        |
| Microneedle applicator device .....   | 51        |
| Nanoject™ microneedle technology .....  | 51        |
| Silk microneedles .....   | 51        |
| ZP Patch microprojections technology .....  | 52        |
| Companies developing microneedles for transdermal drug delivery .....             | 52        |
| <b>Needlefree injections</b> .....  | <b>53</b> |
| Glide SDI® solid dose injector .....  | 53        |
| Jet injection .....   | 53        |
| Mini-Ject needlefree delivery system .....  | 54        |
| MicroJet for painless injections .....  | 54        |
| Nanoliter-volume pulsed microjets .....   | 54        |
| SUMAVEL™ DosePro™ needle-less injection .....                                     | 55        |
| <b>Skin ablation or abrasion for drug delivery</b> .....                          | <b>55</b> |
| <b>Nanotechnology-based transdermal drug delivery</b> .....                       | <b>55</b> |
| Delivery of nanostructured drugs from transdermal patches .....                   | 56        |
| Effect of mechanical flexion on penetration of bucky balls through the skin ..... | 56        |
| Nanoparticles and nanoemulsions for skin disorders .....                          | 56        |
| Nanotechnology-based transdermal vaccination and immunotherapy .....              | 56        |
| NanoCyte transdermal drug delivery system .....                                   | 57        |
| Safety issues of applications of nanomaterial carriers on the skin .....          | 57        |
| Transdermal administration of lipid nanocapsules .....                            | 58        |
| Transdermal nanoparticle preparations for systemic effect .....                   | 58        |
| <b>Comparison of transdermal drug delivery systems</b> .....                      | <b>59</b> |
| <b>Transdermal drug design</b> .....  | <b>59</b> |
| <b>In vitro testing of transdermal drug delivery systems</b> .....                | <b>59</b> |
| <b>In vivo testing of drug delivery systems</b> .....                             | <b>60</b> |
| Infrared spectroscopy for evaluation of transdermal drug delivery .....           | 61        |
| <b>Modeling of transport through the skin</b> .....                               | <b>61</b> |
| <b>Concluding remarks on transdermal drug delivery technologies</b> .....         | <b>62</b> |
| <b>Future developments in transdermal drug delivery</b> .....                     | <b>62</b> |

|  |           |
|--|-----------|
| <b>3. Transdermal Therapeutics</b> .....                                     | <b>65</b> |
| <b>Introduction</b> .....  | <b>65</b> |
| <b>Drugs that can be administered transdermally</b> .....                    | <b>65</b> |
| <b>Skin disorders</b> .....  | <b>68</b> |
| Psoriasis .....  | 68        |
| <i>Nanoemulsions for paclitaxel delivery in psoriasis</i> .....              | 68        |
| <i>Iontophoresis for treatment of psoriasis</i> .....                        | 68        |
| Hair loss .....  | 68        |
| <b>Cardiovascular disorders</b> .....  | <b>69</b> |
| Angina pectoris .....  | 69        |
| Transdermal drug delivery for hypertension .....                             | 70        |
| Transdermal beta blockers .....  | 70        |
| Transdermal anticoagulants .....   | 71        |
| Congestive heart failure .....   | 71        |
| <b>Respiratory diseases</b> .....  | <b>71</b> |
| Asthma .....   | 71        |
| Chronic obstructive pulmonary disease .....                                  | 72        |
| <b>Neurological and psychiatric disorders</b> .....                          | <b>72</b> |
| Parkinson's disease .....  | 72        |
| <i>Transdermal drug delivery for Parkinson's disease</i> .....               | 73        |
| <i>Transdermal dopamine agonists for Parkinson's disease</i> .....           | 73        |
| <i>Rotigotine</i> .....  | 74        |
| <i>Transdermal administration of other drugs for Parkinson disease</i> ..... | 76        |
| Depression .....   | 76        |

|  |            |
|--|------------|
| <i>Transdermal selegiline</i> .....  | 76         |
| Bipolar disorder .....   | 77         |
| <i>Transdermal lithium</i> .....   | 77         |
| Restless legs syndrome .....   | 77         |
| Alzheimer's disease .....  | 77         |
| Transdermal nicotine for Tourette syndrome .....                             | 78         |
| Attention deficit hyperactivity disorder.....                                | 78         |
| <i>Transdermal methylphenidate</i> .....                                     | 79         |
| Migraine .....   | 79         |
| <i>Transdermal lidocaine</i> .....   | 79         |
| <i>Transdermal sumatriptan</i> .....   | 79         |
| Epilepsy.....  | 80         |
| Tinnitus/Vertigo.....  | 80         |
| Transdermal nitroglycerin for vasospasm due to subarachnoid hemorrhage.....  | 81         |
| <b>Musculoskeletal disorders.....</b>  | <b>81</b>  |
| Osteoporosis .....   | 81         |
| <i>Transdermal alendronate</i> .....   | 81         |
| <i>Transdermal estrogen</i> .....  | 81         |
| <i>Transdermal human parathyroid hormone</i> .....                           | 82         |
| Osteoarthritis .....   | 82         |
| <b>Transdermal therapy of diabetes .....</b>                                 | <b>82</b>  |
| Transdermal insulin delivery in diabetes.....                                | 82         |
| Transdermal GLP1 agonist.....  | 83         |
| <b>Male sexual disorders .....</b>   | <b>84</b>  |
| Erectile dysfunction.....  | 84         |
| <i>Topical and transdermal preparation for erectile dysfunction</i> .....    | 84         |
| Hypogonadism in the male.....  | 84         |
| <i>Topical testosterone</i> .....  | 85         |
| <b>Women's health .....</b>  | <b>86</b>  |
| Female sexual arousal disorder.....  | 86         |
| Menopause.....   | 87         |
| <i>Hormone replacement therapy for menopause</i> .....                       | 87         |
| <i>Effect of transdermal estradiol on bone density</i> .....                 | 89         |
| <i>Transdermal PTH for postmenopausal osteoporosis</i> .....                 | 89         |
| <i>Transdermal testosterone for low libido in postmenopausal women</i> ..... | 89         |
| Breast disorders .....   | 90         |
| Dysmenorrhea.....  | 90         |
| Female infertility .....   | 90         |
| <b>Contraception .....</b>   | <b>91</b>  |
| Female contraception .....   | 91         |
| <i>Ortho Evra™</i> .....   | 91         |
| <i>BAY86-5016</i> .....  | 92         |
| Male contraception.....  | 92         |
| <i>Transdermal progestin plus testosterone</i> .....                         | 92         |
| <b>Cancer .....</b>  | <b>93</b>  |
| Nanoemulsion-based delivery of caffeine for skin cancer .....                | 93         |
| Transcutaneous electroporation for anticancer drugs .....                    | 93         |
| Transdermal drug delivery for prostate cancer .....                          | 94         |
| <i>Transdermal nitroglycerine for prostate cancer</i> .....                  | 94         |
| <i>Transdermal estradiol gel for prostate cancer</i> .....                   | 94         |
| Transdermal drug delivery for breast cancer.....                             | 94         |
| <i>Afimoxifene topical gel for breast cancer</i> .....                       | 94         |
| <b>Pain .....</b>  | <b>94</b>  |
| Relief of pain associated with minor medical procedures .....                | 95         |
| Transdermal Lidoderm® for postherpetic neuralgia .....                       | 95         |
| Nonsteroidal antiinflammatory drugs .....                                    | 95         |
| <i>Topical NSAIDs</i> .....  | 96         |
| <i>Transdermal ketoprofen</i> .....  | 97         |
| <i>Topical opioids</i> .....   | 98         |
| Cancer pain.....   | 98         |
| <i>Transdermal fentanyl</i> .....  | 98         |
| <i>Transdermal nitroglycerine as an adjuvant to opioids</i> .....            | 99         |
| <i>Transdermal buprenorphine</i> .....                                       | 99         |
| Chronic pain of non-malignant origin .....                                   | 99         |
| Transdermal local anesthetics.....   | 100        |
| Postoperative pain .....   | 100        |
| <i>Transdermal fentanyl for the management of postoperative pain</i> .....   | 100        |
| <i>Fibromyalgia</i> .....  | 101        |
| <b>Nausea and vomiting .....</b>   | <b>101</b> |
| Motion sickness .....  | 101        |
| Postoperative vomiting .....   | 101        |

|  |            |
|--|------------|
| Chemotherapy-induced nausea and vomiting .....                                   | 101        |
| <b>Antiaging strategies .....</b>  | <b>102</b> |
| <b>Smoking cessation .....</b>   | <b>102</b> |
| Transdermal nicotine replacement.....  | 102        |
| Use of nicotine patch for smoking cessation in pregnancy .....                   | 103        |
| Other methods of nicotine replacement .....                                      | 103        |
| Other treatments for smoking cessation.....                                      | 104        |
| <b>Miscellaneous uses of transdermal drug delivery.....</b>                      | <b>104</b> |
| Chronic fatigue syndrome .....   | 104        |
| <i>Topical androgenic steroid therapy .....</i>                                  | <i>104</i> |
| Overactive bladder and urinary incontinence .....                                | 104        |
| <i>Transdermal oxybutynin .....</i>  | <i>105</i> |
| Viral infections.....  | 105        |
| <i>Transdermal nanoparticles for immune enhancement in HIV.....</i>              | <i>105</i> |
| <b>Transdermal gene therapy .....</b>  | <b>106</b> |
| Transdermal delivery of plasmid DNA by electroporation.....                      | 106        |
| <b>Transdermal antisense therapy .....</b>                                       | <b>107</b> |
| <b>Transdermal vaccination.....</b>  | <b>107</b> |
| The skin as an immune organ.....   | 108        |
| Technologies for transdermal vaccination .....                                   | 108        |
| <i>Electroporation for administering DNA vaccines .....</i>                      | <i>108</i> |
| <i>Intradermal delivery of cancer vaccines by adenoviral vectors .....</i>       | <i>108</i> |
| <i>Microneedles for transdermal delivery of vaccines .....</i>                   | <i>109</i> |
| <i>Needle-free delivery of vaccines.....</i>                                     | <i>110</i> |
| <i>Transcutaneous immunization .....</i>   | <i>110</i> |
| Applications of transdermal vaccination .....                                    | 110        |
| <i>HIV/AIDS vaccination by topical application.....</i>                          | <i>110</i> |
| <i>Transdermal DNA influenza vaccine.....</i>                                    | <i>111</i> |
| <i>Transdermal A<math>\beta</math> vaccination for Alzheimer's disease .....</i> | <i>111</i> |
| <i>Transdermal vaccination for traveller's diarrhoea .....</i>                   | <i>112</i> |
| Transdermal neutraceuticals.....   | 112        |
| <b>Complications of transdermal therapy .....</b>                                | <b>113</b> |
| Adverse effects of drugs .....   | 113        |
| Overdose effect .....  | 113        |
| Skin complications .....   | 113        |
| <b>4. Markets for Transdermal Drug Delivery .....</b>                            | <b>116</b> |
| <b>Introduction .....</b>  | <b>116</b> |
| <b>Global markets for drug delivery .....</b>                                    | <b>116</b> |
| <b>Geographical distribution of transdermal drug delivery markets .....</b>      | <b>117</b> |
| Emerging transdermal drug delivery markets in Asia .....                         | 117        |
| <b>Transdermal technology markets in therapeutic areas .....</b>                 | <b>117</b> |
| Angina pectoris.....   | 118        |
| Attention deficit hyperactivity disorder.....                                    | 118        |
| Erectile dysfunction.....  | 118        |
| Hypertension.....  | 119        |
| Pain therapeutics .....  | 119        |
| Parkinson's disease .....  | 119        |
| Smoking cessation .....  | 119        |
| Transdermal hormone replacement therapy for menopause .....                      | 119        |
| Transdermal testosterone replacement therapy for hypogonadism in the male .....  | 120        |
| Transdermal contraceptive market .....   | 120        |
| <b>Markets according to transdermal technologies.....</b>                        | <b>120</b> |
| Markets for microneedle-based transdermal drug delivery.....                     | 121        |
| <b>Marketing strategies for transdermal drug delivery.....</b>                   | <b>121</b> |
| <b>Marketing advantages of transdermal drug delivery.....</b>                    | <b>121</b> |
| <b>Unmet needs in transdermal drug delivery .....</b>                            | <b>122</b> |
| <b>Future prospects of transdermal drug delivery .....</b>                       | <b>123</b> |
| Prospects of transdermal delivery for drugs coming off patents.....              | 123        |
| Transdermal delivery of cosmetics .....  | 124        |
| <b>5. Companies involved in transdermal drug delivery .....</b>                  | <b>126</b> |
| <b>Profiles of companies.....</b>  | <b>126</b> |
| <b>Collaborations.....</b>   | <b>264</b> |
| <b>6. References.....</b>  | <b>268</b> |

## Tables

|   |     |
|---|-----|
| Table 1-1: Historical landmarks in the development of transdermal drug delivery .....   | 11  |
| Table 1-2: Transdermal vs oral and intravenous drug delivery .....                      | 13  |
| Table 2-1: Technologies for transdermal drug delivery .....                             | 17  |
| Table 2-2: Chemical enhancers of skin penetration .....                                 | 22  |
| Table 2-3: Drug-in-adhesive versus reservoir type of transdermal patch.....             | 27  |
| Table 2-4: Companies developing transdermal patches for drug delivery .....             | 28  |
| Table 2-5: Companies with technologies for drug delivery by iontophoresis.....          | 36  |
| Table 2-6: Companies involved in electroporation-based drug delivery .....              | 39  |
| Table 2-7: Companies developing microneedles for transdermal drug delivery.....         | 52  |
| Table 2-8: Comparison of transdermal drug delivery systems.....                         | 59  |
| Table 3-1: Approved transdermal products .....  | 65  |
| Table 3-2: Transdermal drugs in clinical trials or approval process .....               | 67  |
| Table 4-1: Worldwide drug delivery market growth 2011 to 2021 .....                     | 116 |
| Table 4-2: Transdermal drug delivery markets for geographical regions 2011 to 2021..... | 117 |
| Table 4-3: Potential therapeutic markets for transdermal products 2011-2021 .....       | 118 |
| Table 4-4: Markets according to transdermal technologies .....                          | 120 |
| Table 4-5: Marketing strategies based on transdermal drug delivery technologies.....    | 121 |
| Table 5-1: Collaborations in transdermal drug delivery .....                            | 264 |

## Figures

|   |     |
|---|-----|
| Figure 1-1: Basic structure of the skin .....   | 12  |
| Figure 1-2: Events governing transcutaneous drug absorption .....                         | 15  |
| Figure 2-1: Basic structure and function of transdermal drug delivery systems.....        | 27  |
| Figure 2-2: A schematic view of electroporation.....                                      | 32  |
| Figure 2-3: Depiction of breakdown of the stratum corneum during electroporation .....    | 33  |
| Figure 2-4: A schematic drawing of Iontophoresis.....                                     | 34  |
| Figure 2-5: SonoPrep ultrasonic skin permeation .....                                     | 42  |
| Figure 2-6: A schematic drawing of the microneedle patch.....                             | 46  |
| Figure 3-1: Oral versus transdermal administration of a drug in Parkinson's disease ..... | 75  |
| Figure 4-1: Unmet needs in transdermal drug delivery .....                                | 123 |